Clinical indications and future directions of carbon-ion radiotherapy: a narrative review
The Ewha Medical Journal · 31.10.2024 · 47 (4)
DOI: 10.12771/emj.2024.e56 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Ewha Medical Journal, online erschienen am 31.10.2024. Verfasst von Seo Hee Choi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Heavy Ion Therapy Research Institute, Yonsei Cancer Center, Yonsei University Health System, Yonsei University Coll…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Health & Welfare.
Abstract (Originalsprache)
Carbon-ion radiotherapy (CIRT) offers superior dose distributions and greater biological effectiveness than conventional photon-based radiotherapy (RT). Due to its higher linear energy transfer and relative biological effectiveness, CIRT is particularly effective against radioresistant tumors and those located near critical organs. Since the first dedicated CIRT facility was established in Japan in 1994, CIRT has demonstrated remarkable efficacy against various malignancies, including head and neck tumors, skull base and upper cervical spine tumors, non-small-cell lung cancer, hepatocellular carcinoma, pancreatic cancer, prostate cancer, and bone and soft tissue sarcomas. This narrative review provides a comprehensive overview of the current status of CIRT, highlighting its clinical indications and future directions. According to clinical studies, CIRT achieves high local control rates with manageable toxicity across multiple cancer types. For instance, in head and neck tumors (e.g., adenoid cystic carcinoma and mucosal melanoma), CIRT has achieved local control rates exceeding 80%. In early-stage non-small-cell lung cancer, CIRT has resulted in local control rates over 90% with minimal toxicity. Moreover, CIRT has shown promise in treating challenging cases of hepatocellular carcinoma and pancreatic cancer, where conventional therapies are limited. Nonetheless, the global adoption of CIRT remains limited due to high costs and complexity. Future directions include conducting randomized controlled trials to establish high-level evidence, integrating new technologies such as ultrahigh-dose-rate (FLASH) therapy, and expanding CIRT facilities globally with strategic planning and cost-effectiveness analyses. If these challenges are addressed, CIRT is poised to play a transformative role in cancer treatment, improving survival rates and the quality of life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Heavy Ion Therapy Research Institute, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
ORCID-Profile: Seo Hee Choi, Woong Sub Koom, Hong In Yoon, Kyung Hwan Kim, Chan Woo Wee, Jaeho Cho, Yong Bae Kim, Ki Chang Keum, Ik Jae Lee
Förderung
- National Research Foundation of Korea
- Ministry of Health & Welfare
Zitieren
APA
Choi, S. H., Koom, W. S., Yoon, H. I., Kim, K. H., Wee, C. W., Cho, J., Kim, Y. B., Keum, K. C., & Lee, I. J. (2024). Clinical indications and future directions of carbon-ion radiotherapy: a narrative review. The Ewha Medical Journal, 47(4). https://doi.org/10.12771/emj.2024.e56
Vancouver
Choi SH, Koom WS, Yoon HI, Kim KH, Wee CW, Cho J, et al. Clinical indications and future directions of carbon-ion radiotherapy: a narrative review. The Ewha Medical Journal. 2024;47(4). doi:10.12771/emj.2024.e56
BibTeX
@article{Choi2024,
author = {Choi, Seo Hee and Koom, Woong Sub and Yoon, Hong In and Kim, Kyung Hwan and Wee, Chan Woo and Cho, Jaeho and Kim, Yong Bae and Keum, Ki Chang and Lee, Ik Jae},
title = {Clinical indications and future directions of carbon-ion radiotherapy: a narrative review},
journal = {The Ewha Medical Journal},
year = {2024},
volume = {47},
number = {4},
doi = {10.12771/emj.2024.e56}
}
EUVIMED